In time-to-event analyses controlling for thrombosis risk factors, the ALK rearrangement conferred a fourfold increase in VTE risk and a threefold increase in arterial thrombosis risk in NSCLC. These patients may benefit from pharmacologic thromboprophylaxis. READ ARTICLE
Journal of Thoracic Oncology DOI: 10.1016/j.jtho.2020.04.033
Authors: Hanny Al-Samkari, Orly Leiva, Ibiayi Dagogo-Jack, Alice Shaw, Jochen Lennerz, Anthony J Iafrate, Pavan K Bendapudi, Jean M Connors
Read More